Concord Drugs

Which are the latest news on Concord Drugs?

Why is Concord Drugs Ltd falling/rising?

As of 05-Sep, Concord Drugs Ltd's stock price is rising to 80.82, driven by strong financial results, including an 825% growth in net profit and a 53.93% increase in net sales. The stock has outperformed its sector and the broader market, despite a decrease in promoter holding.

As of 05-Sep, Concord Drugs Ltd's stock price is rising, currently at 80.82, with a change of 0.51 (0.64%) upwards. This increase can be attributed to several positive factors. The stock has outperformed its sector by 1.3% today and has experienced consecutive gains over the last two days, resulting in a total return of 2.88% during this period. Additionally, Concord Drugs is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend.<BR><BR>The company has reported outstanding financial results, including a remarkable 825% growth in net profit and a 53.93% increase in net sales for the last quarter. Furthermore, the stock has generated a return of 26.28% over the past year, significantly outperforming the broader market, which saw a return of only 1.51%. The attractive valuation metrics, such as a PEG ratio of 0.2 and a low enterprise value to capital employed ratio of 1.9, also contribute to investor confidence.<BR><BR>However, it is important to note that there has been a decrease in promoter holding, which now stands at 45.08%. Despite this, the overall positive financial performance and market-beating returns are driving the stock's rise.

Who are in the management team of Concord Drugs?

The management team of Concord Drugs includes S Nagi Reddy (Chairman & Managing Director), K Ramchandra Reddy (Independent Director), Koni Reddy (Whole Time Director & CFO), S. Nagavenkata Hareesh (Independent Director), S. Manoj Kumar Reddy (Whole-time Director), and Summela Kasu (Independent Director). They oversee the company's operations and strategic direction.

The management team of Concord Drugs includes the following individuals:<BR><BR>1. **S Nagi Reddy** - Chairman & Managing Director<BR>2. **K Ramchandra Reddy** - Independent Director<BR>3. **Koni Reddy** - Whole Time Director & CFO<BR>4. **S. Nagavenkata Hareesh** - Independent Director<BR>5. **S. Manoj Kumar Reddy** - Whole-time Director<BR>6. **Summela Kasu** - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Concord Drugs do?

Concord Drugs Ltd is a pharmaceutical company established in 1995, specializing in finished pharmaceutical formulations with a market cap of INR 104 Cr. As of June 2026, it reported net sales of 21 Cr and a net profit of 1 Cr.

Overview: <BR>Concord Drugs Ltd is a pharmaceutical company specializing in the manufacturing of finished pharmaceutical formulations, operating within the Micro Cap market segment.<BR><BR>History: <BR>Concord Drugs Ltd was established in 1995 and has maintained its status as a respected player in the pharmaceutical industry. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 21 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 1 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 104 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 51.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.26 <BR>Return on Equity: 2.18% <BR>Price to Book: 2.25<BR><BR>Contact Details: <BR>Address: Survey No 249 Brahmanapally V, Hayathnagar M Ranga Reddy Telangana : 501511 <BR>Tel: 91-40-24036379 <BR>Email: concorddrugsltd@gmail.com <BR>Website: http://www.concorddrugs.in

Who are the peers of the Concord Drugs?

Peers of Concord Drugs include Makers Labs, Tyche Industries, Pharmaids Pharma, Godavari Drugs, Veerhealth Care, Denis Chem Lab, Mercury Labs, Vaishali Pharma, and Sotac Pharma. Concord Drugs has a 1-year return of 29.93%, lower than Veerhealth Care's 157.30% but higher than Pharmaids Pharma's -46.61%.

Peers: The peers of Concord Drugs are Makers Labs., Tyche Industries, Pharmaids Pharma, Godavari Drugs, Veerhealth Care, Denis Chem Lab, Mercury Labs, Vaishali Pharma, and Sotac Pharma.<BR><BR>Quality Snapshot: Below Average management risk is observed at Makers Labs., Pharmaids Pharma, Godavari Drugs, Concord Drugs, Veerhealth Care, Vaishali Pharma, and Sotac Pharma, while Average management risk is found at Tyche Industries and Mercury Labs. Good management risk is noted at Denis Chem Lab. Below Average growth is seen at Makers Labs., Pharmaids Pharma, Godavari Drugs, Concord Drugs, and Vaishali Pharma, while Average growth is found at Sotac Pharma. Good growth is observed at Veerhealth Care, and Average growth is noted at Tyche Industries and Mercury Labs. Below Average capital structure is present at Makers Labs., Pharmaids Pharma, Godavari Drugs, Concord Drugs, and Vaishali Pharma, while Excellent capital structure is noted at Tyche Industries and Denis Chem Lab. Good capital structure is seen at Veerhealth Care and Mercury Labs.<BR><BR>Return Snapshot: Veerhealth Care has the highest 1-year return at 157.30%, while Pharmaids Pharma has the lowest at -46.61%. Concord Drugs has a 1-year return of 29.93%, which is significantly higher than Pharmaids Pharma but lower than Veerhealth Care. Additionally, Denis Chem Lab, Mercury Labs, and Vaishali Pharma have negative six-month returns.

How big is Concord Drugs?

As of 31st August, Concord Drugs Ltd has a market capitalization of 104.00 Cr, with net sales of 86.12 Cr and a net profit of 2.05 Cr over the latest four quarters.

As of 31st August, Concord Drugs Ltd has a market capitalization of 104.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Concord Drugs reported net sales of 86.12 Cr and a net profit of 2.05 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with shareholder's funds amounting to 34.11 Cr and total assets of 65.14 Cr.

Should I buy, sell or hold Concord Drugs Ltd?

When is the next results date for Concord Drugs Ltd?

The next results date for Concord Drugs Ltd is 10 August 2026.

The next results date for Concord Drugs Ltd is scheduled for 10 August 2026.

Are Concord Drugs Ltd latest results good or bad?

Concord Drugs Ltd's latest results show impressive revenue growth of 264.77% and a significant profit increase, but low profit margins and a high P/E ratio raise concerns about profitability and valuation. Investors should consider these factors when assessing the company's performance.

Concord Drugs Ltd's latest results present a mixed picture. On one hand, the company reported a remarkable year-on-year revenue growth of 264.77% in Q4 FY26, with net sales reaching ₹37.90 crores. This surge is indicative of strong demand or successful order fulfillment. Additionally, net profit for the quarter increased significantly to ₹0.53 crores, reflecting a staggering 1,225.00% growth compared to the same quarter last year.<BR><BR>However, despite this impressive revenue and profit growth, there are significant concerns regarding profitability. The profit after tax (PAT) margin remains low at just 1.40%, and the operating margin has contracted to 3.93%, down from higher levels in previous periods. This suggests that while revenue is increasing, the company is facing challenges in managing costs and maintaining pricing power.<BR><BR>Furthermore, the return on equity (ROE) is quite low at 1.69%, indicating inefficiencies in capital utilization. The company's elevated valuation, trading at a P/E ratio of 191.62x, raises questions about whether the current stock price accurately reflects its fundamental performance.<BR><BR>In summary, while Concord Drugs has demonstrated exceptional revenue growth and a significant profit turnaround in the latest quarter, the underlying profitability metrics and high valuation suggest caution. Investors should weigh these factors carefully when evaluating the company's performance.

Is Concord Drugs overvalued or undervalued?

As of December 2, 2025, Concord Drugs is considered undervalued with a PE Ratio of 135.16 and a PEG Ratio of 0.63, outperforming peers like Sun Pharma and Divi's Lab, and achieving a year-to-date return of 106.29% compared to the Sensex's 8.96%.

As of 2 December 2025, Concord Drugs has moved from a fair to an attractive valuation grade. The company is currently considered undervalued, particularly in comparison to its peers in the pharmaceuticals and biotechnology sector. Notable ratios include a PE Ratio of 135.16, an EV to EBITDA of 20.90, and a PEG Ratio of 0.63, indicating potential growth relative to its price.<BR><BR>In comparison to its peers, Concord Drugs stands out with its attractive valuation, while Sun Pharma has a PE of 37.36 and an EV to EBITDA of 24.69, and Divi's Lab is even more expensive with a PE of 68.62 and an EV to EBITDA of 51.56. Despite a recent decline in stock price, Concord Drugs has significantly outperformed the Sensex over various periods, including a year-to-date return of 106.29% compared to the Sensex's 8.96%. This performance reinforces the view that the company is undervalued relative to its growth potential.

How has been the historical performance of Concord Drugs?

Concord Drugs has experienced a declining trend in net sales and profits over the past four years, with net sales at 45.25 Cr in March 2025, down from 59.06 Cr in March 2022. Despite a slight increase in some metrics in 2025, overall financial performance remains challenging.

Answer:<BR>The historical performance of Concord Drugs shows a declining trend in net sales and profits over the past four years.<BR><BR>Breakdown:<BR>Concord Drugs reported net sales of 45.25 Cr in March 2025, a slight increase from 44.93 Cr in March 2024, but a decrease from 52.09 Cr in March 2023 and 59.06 Cr in March 2022. Total operating income mirrored this trend, remaining at 45.25 Cr in March 2025, up from 44.93 Cr in March 2024, but down from 52.09 Cr in March 2023 and 59.06 Cr in March 2022. The total expenditure, excluding depreciation, was 41.11 Cr in March 2025, up from 40.88 Cr in March 2024, but down from 47.50 Cr in March 2023 and 53.37 Cr in March 2022. Operating profit (PBDIT) was 4.14 Cr in March 2025, a slight increase from 4.05 Cr in March 2024, but lower than 4.59 Cr in March 2023 and 5.69 Cr in March 2022. Profit before tax was 0.69 Cr in March 2025, up from 0.63 Cr in March 2024, but significantly down from 1.25 Cr in March 2023 and 2.25 Cr in March 2022. Profit after tax also decreased to 0.34 Cr in March 2025 from 0.47 Cr in March 2024, 0.99 Cr in March 2023, and 1.59 Cr in March 2022. The total assets of the company increased to 65.14 Cr in March 2025 from 58.81 Cr in March 2024, while total liabilities rose to 65.14 Cr from 58.81 Cr in the same period. Cash flow from operating activities was 3.00 Cr in March 2025, showing improvement from 0.00 Cr in March 2024, while cash flow from investing activities was -2.00 Cr, and cash flow from financing activities was -1.00 Cr. Overall, the financial metrics indicate a challenging performance trajectory for Concord Drugs over the past four years.

What is the technical trend for Concord Drugs?

As of June 5, 2025, Concord Drugs is in a mildly bearish trend, with daily moving averages and weekly Bollinger Bands indicating bearish signals, while mixed signals from weekly MACD and KST, along with a neutral RSI, suggest moderate bearish strength influenced by recent price action.

As of 5 June 2025, the technical trend for Concord Drugs has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish trend and the weekly Bollinger Bands also showing a mildly bearish signal. While the weekly MACD and KST are mildly bullish, the monthly indicators remain bearish, suggesting mixed signals across different time frames. The RSI shows no signals, indicating a lack of momentum in either direction. Overall, the strength of the bearish trend is moderate, influenced by the recent price action and the broader market context.

Who are the top shareholders of the Concord Drugs?

The top shareholders of Concord Drugs include promoter Nagi Reddy Seelam with 28.61% ownership, while individual investors hold 43.33%. The highest public shareholder is Pradeep Kumar Jain at 1.89%, and there are no mutual funds or foreign institutional investors involved.

The top shareholders of Concord Drugs include the promoters, who hold the majority of the shares. The promoter with the highest holding is Nagi Reddy Seelam, who owns 28.61% of the company. Additionally, individual investors collectively hold 43.33% of the shares. The highest public shareholder is Pradeep Kumar Jain, with a holding of 1.89%. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company.

Has Concord Drugs declared dividend?

No Dividend History Available